Aastrom Biosciences To Present at BMO Capital Markets Healthcare Conference
01 December 2006 - 6:30AM
PR Newswire (US)
ANN ARBOR, Mich., Nov. 30 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM), a clinical development stage
company focused on the use of autologous cells for regenerative
medicine, today announced that George W. Dunbar, President and
Chief Executive Officer, and Elmar R. Burchardt, M.D., Ph.D., will
present at the 2006 BMO Capital Markets Focus on Healthcare
Conference. The conference will be held December 6-7th at the
Millennium Broadway Hotel in New York City. Aastrom will present on
Thursday, December 7, 2006 at 9:15 a.m. (Eastern Time). (Logo:
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO ) A live
audio webcast of Aastrom's presentation can be accessed by logging
onto the web at http://www.bmocm.com/conferences/healthcare2006 ,
and clicking on the "Audio Webcast" button. A replay of the
presentation will be archived until the conclusion of the
conference on December 7th, at the same site. For more information,
please visit the conference website at
http://www.bmocm.com/conferences/healthcare2006/default.aspx .
About Aastrom Biosciences, Inc. Aastrom Biosciences, Inc.
(NASDAQ:ASTM) is developing autologous cell products for the repair
or regeneration of multiple human tissues, based on its proprietary
Tissue Repair Cell (TRC) technology. Aastrom's TRC-based products
are a unique cell mixture containing stem and progenitor cell
populations, produced from a small amount of bone marrow taken from
the patient. TRC-based products have been used in over 230
patients, and are currently in clinical trials for bone
regeneration (long bone fractures and spine fusion) and vascular
regeneration (critical limb ischemia) applications. Aastrom has
reported positive interim clinical trial results for TRCs
suggesting both the clinical safety and the ability of TRCs to
promote healing in bone regeneration applications. The Company's
proprietary TRCs received an Orphan Drug Designation from the U.S.
Food and Drug Administration (FDA) for use in the treatment of
osteonecrosis of the femoral head. In addition, Aastrom is
developing plans for TRC-based therapies to address cardiac and
neural regeneration indications. For more information, visit
Aastrom's website at http://www.aastrom.com/ . This document
contains forward-looking statements, including without limitation,
statements regarding product development objectives, market
development plans, and potential advantages and applications of
Tissue Repair Cells, which involve certain risks and uncertainties.
The forward-looking statements are also identified through use of
the words "plans," and other words of similar meaning. Actual
results may differ significantly from the expectations contained in
the forward-looking statements. Among the factors that may result
in differences are the results obtained from clinical trial
activities, regulatory approval requirements, and the availability
of resources. These and other significant factors are discussed in
greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly Cameron Associates Investor Relations Department Kevin
McGrath Aastrom Biosciences, Inc. Phone: (212) 245-4577 Phone:
(734) 930-5777 Deanne Eagle (Media) Phone: (212) 554-5463
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO
http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly, Investor Relations Department, Aastrom
Biosciences, Inc., +1-734-930-5777; Cameron Associates: Kevin
McGrath, +1-212-245-4577, Deanne Eagle (Media), +1-212-554-5463 Web
site: http://www.aastrom.com/
http://www.bmocm.com/conferences/healthcare2006
http://www.bmocm.com/conferences/healthcare2006/default.aspx
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024